Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Globe Newswire - Tue Aug 9, 2022

Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase

CAPLYTA net product revenues for the second quarter 2022 were $55.1 million, representing a 190% increase over the same period in 2021 and a 58% increase over the first quarter 2022

Read more at globenewswire.com